Is CJC-1295 or ipamorelin better for GH release?
Neither — they engage different receptors and produce different GH-release patterns rather than competing on a “better” dimension. CJC-1295 No DAC engages the GHRH receptor; ipamorelin engages the ghrelin receptor (GHSR-1a). The two pathways are complementary and the combined-research format engages both simultaneously.
What the research literature says
The pituitary somatotroph cell expresses both the GHRH receptor and the growth hormone secretagogue receptor (GHSR-1a, the ghrelin receptor). The two receptors signal through independent G-protein-coupled receptor cascades — GHRH receptor through Gαs/cAMP/PKA, ghrelin receptor through Gαq/IP3/calcium — converging on GH-release machinery downstream. Engagement of either receptor produces GH release; engagement of both produces additive or synergistic GH release without receptor cross-desensitisation.
CJC-1295 No DAC’s GHRH-receptor agonism was characterised across the Jetté identification work (PMID 15817669), the Teichman clinical-pharmacology study (PMID 16352683), and the Ionescu pulsatile-GH work (PMID 17018654). Ipamorelin’s selective ghrelin-receptor agonism was characterised in the Raun first-selective-GHS paper (PMID 9849822) with pharmacokinetic profile in the Johansen work (PMID 9879640).
The published research community’s combined-protocol convention pairs the two compounds rather than choosing between them. The Ronin catalog supplies both as standalone vials and as a combined-formulation single vial (CJC-1295 + Ipamorelin Blend, 5 mg + 5 mg fixed loadings).
Why this matters in research context
The framing “better” is the wrong axis for the comparison. Researchers studying GHRH-receptor pharmacology use CJC-1295; researchers studying ghrelin-receptor pharmacology use ipamorelin; researchers studying integrated GH-axis pharmacology use both. The combined-research format simplifies the operational handling.
Related compounds
- CJC-1295 No DAC 10mg — GHRH-receptor agonist
- Ipamorelin 10mg — selective ghrelin-receptor agonist
- CJC-1295 + Ipamorelin Blend — single-vial combination
Related research questions
- Can CJC-1295 be stacked with ipamorelin?
- What is the half-life of CJC-1295 No DAC?
- What is the half-life of ipamorelin?
References
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139(5):552-561. [PMID 9849822]
- Johansen PB et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica 1998;28(11):1083-1095. [PMID 9879640]
- Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005;146(7):3052-3058. [PMID 15817669]
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91(3):799-805. [PMID 16352683]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.